Systemic administration of drugs in tumors is a challenging task due to unorganized microvasculature and nonuniform extravasation. There is an imperative need to understand the transport behavior of drugs when administered intravenously. In this study, a transport model is developed to understand the therapeutic efficacy of a free drug and liposome-encapsulated drugs (LED), in heterogeneous vasculature of human brain tumors. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) data is employed to model the heterogeneity in tumor vasculature that is directly mapped onto the computational fluid dynamics (CFD) model. Results indicate that heterogeneous vasculature leads to preferential accumulation of drugs at the tumor position. Higher drug accumulation was found at location of higher interstitial volume, thereby facilitating more tumor cell killing at those areas. Liposome-released drug (LRD) remains inside the tumor for longer time as compared to free drug, which together with higher concentration enhances therapeutic efficacy. The interstitial as well as intracellular concentration of LRD is found to be 2–20 fold higher as compared to free drug, which are in line with experimental data reported in literature. Close agreement between the predicted and experimental data demonstrates the potential of the developed model in modeling the transport of LED and free drugs in heterogeneous vasculature of human tumors.
References
1.
Pattni
, B. S.
, Chupin
, V. V.
, and Torchilin
, V. P.
, 2015
, “New Developments in Liposomal Drug Delivery
,” Chem. Rev.
, 115
(19
), pp. 10938
–10966
.2.
Allen
, T. M.
, and Torchilin
, P. R.
, 2013
, “Liposomal Drug Delivery Systems: From Concept to Clinical Applications
,” Adv. Drug Delivery Rev.
, 65
(1
), pp. 36
–48
.3.
Baxter
, L. T.
, and Jain
, R. K.
, 1989
, “Transport of Fluid and Macromolecules in Tumors—I: Role of Interstitial Pressure and Convection
,” Microvasc. Res.
, 37
(1
), pp. 77
–104
.4.
Baxter
, L. T.
, and Jain
, R. K.
, 1990
, “Transport of Fluid and Macromolecules in Tumors II. Role of Heterogeneous Perfusion and Lymphatics
,” Microvasc. Res.
, 40
(2), pp. 246
–263
.5.
Harashima
, H.
, Iida
, S.
, Urakami
, Y.
, Tsuchihashi
, M.
, and Kiwada
, H.
, 1999
, “Optimization of Antitumor Effect of Liposomally Encapsulated Doxorubicin Based on Simulation by Pharmacokinetic/Pharmacodynamics Modeling
,” J. Controlled Release
, 61
(1–2
), pp. 93
–106
.6.
Elkareh
, A. W.
, and Secomb
, T. W.
, 2000
, “A Mathematical Model for Comparison of Bolus Injection, Continuous Infusion and Liposomal Delivery of Doxorubicin to Tumor Cells
,” Neoplasia
, 2
(4
), pp. 325
–338
.7.
Stapleton
, S.
, Milosevic
, M.
, Allen
, C.
, Zheng
, J.
, Dunne
, M.
, Yeung
, I.
, and Jaffray
, D. A.
, 2013
, “A Mathematical Model of the Enhanced Permeability and Retention Effect for Liposome Transport in Solid Tumors
,” PLoS ONE
, 8
(2
), p. e81157
.8.
Goh
, Y. M. F.
, Kong
, H. L.
, and Wang
, C. H.
, 2001
, “Simulation of Delivery of Doxorubicin to Hepatoma
,” Pharm. Res.
, 18
(6
), pp. 761
–770
.9.
Arifin
, D. Y.
, Lee
, K. Y. T.
, Wang
, C. H.
, and Smith
, K. A.
, 2009
, “Role of Convective Flow in Carmustine Delivery to a Brain Tumor
,” Pharm. Res.
, 26
(10
), pp. 2289
–2302
.10.
Soltani
, M.
, and Chen
, P.
, 2011
, “Numerical Modeling of Fluid Flow in Solid Tumors
,” PLoS One
, 6
(6
), p. e20344
.11.
Zhan
, W.
, Gedroyc
, W.
, and Xu
, X. Y.
, 2014
, “Effect of Heterogeneous Microvasculature Distribution on Drug Delivery to Solid Tumour
,” J. Phys. D: Appl. Phys.
, 47
(47
), p. 475401
.12.
Magdoom
, K. N.
, Pishko
, G. L.
, Kim
, J. H.
, and Sarntinoranont
, M.
, 2012
, “Evaluation of a Voxelized Model Based on DCE-MRI for Tracer Transport in Tumor
,” ASME J. Biomech. Eng.
, 134
(9), p. 091004
.13.
Tofts
, P.S.
, Brix
, G.
, Buckley
, D. L.
, Evelhoch
, J. L.
, Henderson
, E .
, Knopp
, M. V.
, Larsson
, H. B. W.
, Lee
, T. Y.
, Mayr
, N. A.
, Parker
, G. J. M.
, Port
, R. E.
, Taylor
, J.
, and Weisskoff
, R. M.
, 1999
, “Estimating Kinetic Parameters From Dynamic Contrast-Enhanced T1-Weighted MRI of a Diffusable Tracer: Standardized Quantities and Symbols
,” J. Magn. Reson. Imaging
, 26
(4
), pp. 871
–880
.https://www.ncbi.nlm.nih.gov/pubmed/1050828114.
Bhandari
, A.
, Bansal
, A.
, Singh
, A.
, and Sinha
, N.
, 2017
, “Perfusion Kinetics in Human Brain Tumor With DCE-MRI Derived Model and CFD Analysis
,” J. Biomech.
, 59
, pp. 80
–89
.15.
Bhandari
, A.
, Bansal
, A.
, Singh
, A.
, and Sinha
, N.
, 2017
, “Transport of Liposomes Encapsulated Drugs in Voxelized Computational Model of Human Brain Tumors
,” IEEE Trans. Nanobiosci.
, 16
(7
), pp. 634
–644
.16.
Tofts
, P. S.
, 1997
, “Modeling Tracer Kinetics in Dynamic Gd-DTPA MR Imaging
,” J. Magn. Reson. Imaging,
3
, pp. 91
–101
.17.
Singh
, A.
, Haris
, M.
, Purwar
, A.
, Sharma
, M.
, Husain
, N.
, Rathore
, R. K. S.
, and Gupta
, R. K.
, 2007
, “Quantification of Physiological and Hemodynamic Indices Using T1 DCE-MRI in Intracranial Mass Lesions
,” J. Magn. Reson. Imaging
, 26
(4), pp. 871
–880
.18.
Pintaske
, J.
, Martirosian
, P.
, Graf
, H.
, Erb
, G.
, Lodemann
, K. P.
, Claussen
, C. D.
, and Schick
, F.
, 2006
, “Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5 and 3 Tesla
,” Invest. Radiol.
, 41
(3
), pp. 213
–221
.19.
Singh
, A.
, Rathore
, R. K. S.
, Haris
, M.
, Verma
, S. K.
, Husain
, N.
, and Gupta
, R. K.
, 2009
, “Improved Bolus Arrival Time and Arterial Input Function Estimation for Tracer Kinetic Analysis in DCE-MRI
,” J. Magn. Reson. Imaging
, 29
(1), pp. 166
–176
.20.
Tofts
, P. S.
, and Kermode
, A. G.
, 1991
, “Measurement of the Blood-Brain Barrier Permeability and Leakage Space Using Dynamic MR Imaging
,” Magn. Reson. Med.
, 17
(2), pp. 357
–367
.21.
Gabizon
, A.
, Isacson
, R.
, Libson
, E.
, Kaufman
, B.
, Uziely
, B.
, Catane
, R.
, Rabello
, E.
, Cass
, Y.
, Peretz
, T.
, Sulkes
, A.
, Chisin
, R.
, and Barenholz
, Y.
, 1994
, “Clinical Studies of Liposome Encapsulated Doxorubicin
,” Acta Oncol.
, 33
(7
), pp. 779
–786
.22.
Greene
, R. F.
, Collins
, J. M.
, Jenkins
, J. F.
, Speyer
, J. L.
, and Myers
, C. E.
, 1983
, “Plasma Pharmacokinetics of Adriamycin and Adriamycinol: Implications for the Design of In Vitro Experiments and Treatment Protocols
,” Cancer Res.
, 43
(7), pp. 3417
–3421
.http://cancerres.aacrjournals.org/content/43/7/3417.short23.
Eikenberry
, S.
, 2009
, “A Tumor Cord Model for Doxorubicin Delivery and Dose Optimization in Solid Tumors
,” Theor. Bio. Med. Model.
, 6
, p. 16
.24.
Eliaz
, R. E.
, Nir
, S.
, Marty
, C.
, and Szoka
, F. C.
, 2004
, “Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes
,” Cancer Res.
, 64
(2), pp. 711
–718
.25.
Khalifa
, A.
, Dodds
, D.
, Rampling
, R.
, Paterson
, J.
, and Murray
, T.
, 1997
, “Liposomal Distribution in Malignant Gliomas: Possibilities for Theraphy
,” Nucl. Med. Commun.
, 18
, pp. 17
–23
.26.
Hau
, P.
, Fabel
, K.
, Baumgart
, U.
, Rummele
, P.
, Grauer
, O.
, Bock
, A.
, Dietmaier
, C.
, Dietmaier
, W.
, Dietrich
, J.
, Dudel
, C.
, Hubner
, F.
, Jauch
, T.
, Drechsel
, E.
, Kleiter
, I.
, Wismeth
, C.
, Zellner
, A.
, Brawanski
, A.
, Stienbrecher
, A.
, Marienhagen
, J.
, and Bogdahn
, U.
, 2005
, “Pegylated Liposomal Doxorubicin-Efficacy in Patients With Recurrent High-Grade Gliomas
,” Am. Can. Soc.
, 100
(6
), pp. 1199
–1207
.27.
Murray
, J. D.
, 2012
, “Glioblastoma Brain Tumours: Estimating the Time From Brain Tumour Initiation and Resolution of a Patient Survival Anomaly After Similar Treatment Protocols
,” J. Bio. Dyn.
, 6
(2
), pp. 118
–127
.28.
Anderson
, D. A.
, Tannehill
, J. C.
, and Pletcher
, R. H.
, 1984
, Computational Fluid Mechanics and Heat Transfer
, Hemisphere
, New York
, pp. 671
–674
.29.
Abe
, T.
, Mizobuchi
, Y.
, Nakajima
, K.
, Otomi
, Y.
, Irahara
, S.
, Obama
, Y.
, Majigsuren
, M.
, Khashbat
, D.
, Kagezi
, T.
, Nagahiro
, S.
, and Harada
, M.
, 2015
, “Diagnosis of Brain Tumors Using Dynamic Contrast-Enhanced Perfusion Imaging With a Short Acquisition Time
,” Springer Plus
, 4
, p. 88
.30.
Boucher
, Y.
, Salehi
, H.
, Witwer
, B.
, Harsh
, G. R.
, IV., and Jain
, R. K.
, 1997
, “Interstitial Fluid Pressure in Intracranial Tumors in Patients and in Rodents
,” Br. J. Cancer
, 75
, pp. 829
–836
.31.
Guttman
, R.
, Leunig
, M.
, Feyh
, J.
, Goetz
, A. E.
, Messmer
, K.
, and Kastenbauer
, E.
, 1992
, “Interstitial Hypertension in Head and Neck Tumors in Patients: Correlation With Tumor Size
,” Cancer Res.
, 52
(7), pp. 1993
–1995
.http://cancerres.aacrjournals.org/content/52/7/1993.short32.
Wu
, Z. N.
, Da
, D.
, Rudoll
, T. L.
, Needham
, D.
, Whorton
, A. R.
, and Dewhirst
, M. W.
, 1993
, “Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue
,” Cancer Res.
, 53
(16), pp. 3765
–3770
.http://cancerres.aacrjournals.org/content/53/16/3765.short33.
Gabizon
, A.
, Goren
, D.
, Horowitz
, A. T.
, Tzemach
, D.
, Lossos
, A.
, and Siegal
, T.
, 1997
, “Long-Circulating Liposomes for Drug Delivery in Cancer Therapy: A Review of Bio-Distribution Studies in Tumor-Bearing Animals
,” Adv. Drug Delivery Rev.
, 24
(2–3), pp. 337
–344
.34.
Gabizon
, A.
, Shmeeda
, H.
, and Barenholz
, Y.
, 2003
, “Pharmacokinetics of Pegylated Liposomal Doxorubicin, Review of Animal and Human Studies
,” Clin. Pharm.
, 42
(5
), pp. 419
–436
.35.
Gabizon
, A.
, Catane
, R.
, Uziely
, B.
, Kaufman
, B.
, Safra
, T.
, Cohen
, R.
, Martin
, F.
, Huang
, A.
, and Barenholz
, Y.
, 1994
, “Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes
,” Cancer Res.
, 54
(4), pp. 987
–992
.http://cancerres.aacrjournals.org/content/54/4/987.short36.
Siegel
, T.
, Horowitz
, A.
, and Gabizon
, A.
, 1995
, “Doxorubicin Encapsulated in Sterically Stabilized Liposomes for the Treatment of a Brain Tumor Model: Bio Distribution and Therapeutic Efficacy
,” J. Neurosurg.
, 83
(6), pp. 1029
–1037
.Copyright © 2018 by ASME
You do not currently have access to this content.
